{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:51:03Z","timestamp":1786657863334,"version":"build-2736575974"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) - Khargar"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To evaluate the incidence, clinical characteristics and outcomes of second primary malignancies (SPM) in Multiple myeloma patients post autologous stem-cell transplant (ASCT). This is a report of myeloma patients from a prospectively maintained database who underwent ASCT between 1st March, 2007 to 31st December, 2022. Baseline characteristics, details of induction, transplant and post-transplant maintenance therapy of these patients were retrieved. Details of treatment received for SPM, and outcomes were also obtained. In total,178 patients underwent 192 ASCTs (14 patients with two ASCTs). Of 178 patients, six patients (3.3%) developed SPM [3-solid (1.6%) and 3-haematological (1.6%)] at a median follow-up post-ASCT of 8.7 years. Median follow-up of entire cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009178) post-ASCT was 51 months. Median time from diagnosis and transplant to second malignancy was 9.0 years (5.4\u201313.5 years) and 8.2 years (4.0-12.3 years), respectively. Median duration of lenalidomide exposure from diagnosis to second malignancy in these six patients was 25.8 months (Range: 15\u201340 months). Amongst our six patients with SPM, three patients (50%) are alive. At a median follow-up of more than 8 years post-ASCT, the incidence of SPM was 3.3% in our cohort. This highlights the need for life-long surveillance for SPM in myeloma patients post-ASCT.\n                  <\/jats:p>","DOI":"10.1007\/s12288-025-01984-2","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T09:13:35Z","timestamp":1745658815000},"page":"243-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Second Primary Malignancies Post Autologous Stem-cell Transplant in Multiple Myeloma from India \u2013 Knowing the Unknown"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0642-2207","authenticated-orcid":false,"given":"Sumeet","family":"Mirgh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athira","family":"Surendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Punatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anant","family":"Gokarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akanksha","family":"Chichra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingaraj","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Tembhare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Patkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Rajpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papagudi","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5708-6472","authenticated-orcid":false,"given":"Navin","family":"Khattry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"14","key":"1984_CR1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M et al (2017) Lenalidomide, Bortezomib, and dexamethasone with transplantation for Myeloma. N Engl J Med 376(14):1311\u20131320. https:\/\/doi.org\/10.1056\/NEJMoa1611750","journal-title":"N Engl J Med"},{"issue":"2","key":"1984_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS et al (2022) Triplet Therapy, Transplantation, and maintenance until Progression in Myeloma. N Engl J Med 387(2):132\u2013147. https:\/\/doi.org\/10.1056\/NEJMoa2204925","journal-title":"N Engl J Med"},{"issue":"8","key":"1984_CR3","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C et al (2020) Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136(8):936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"issue":"12","key":"1984_CR4","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.3324\/haematol.2023.283202","volume":"108","author":"H Takamatsu","year":"2023","unstructured":"Takamatsu H, Matsuda T, Mizuno S et al (2023) Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs. Haematologica 108(12):3399\u20133408 Published 2023 Dec 1. https:\/\/doi.org\/10.3324\/haematol.2023.283202","journal-title":"Haematologica"},{"issue":"5","key":"1984_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/hon.2923","volume":"39","author":"F Fei","year":"2021","unstructured":"Fei F, Reddy V, Rosenblum F (2021) Secondary primary malignancies in patients with multiple myeloma: a single institution experience. Hematol Oncol 39(5):674\u2013679. https:\/\/doi.org\/10.1002\/hon.2923","journal-title":"Hematol Oncol"},{"key":"1984_CR6","doi-asserted-by":"publisher","unstructured":"Tzeng HE, Lin CL, Tsai CH et al (2013) Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study. PLoS One 8(7):e68041. https:\/\/doi.org\/10.1371\/journal.pone.0068041","DOI":"10.1371\/journal.pone.0068041"},{"key":"1984_CR7","doi-asserted-by":"publisher","unstructured":"Rosenberg AS, Brunson A, Tuscano J et al (2021) Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer J.;11(1):5. Published 2021 Jan 7. https:\/\/doi.org\/10.1038\/s41408-020-00400-4","DOI":"10.1038\/s41408-020-00400-4"},{"key":"1984_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canep.2019.02.010","volume":"59","author":"K Bora","year":"2019","unstructured":"Bora K (2019) Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography. Cancer Epidemiol 59:215\u2013220","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"1984_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12288-019-01111-y","volume":"35","author":"U Yanamandra","year":"2019","unstructured":"Yanamandra U, Malhotra P (2019) Stem cell transplantation in multiple myeloma: very much alive and kicking. Indian J Hematol Blood Transfus (Apr-June 35(2):205\u2013207","journal-title":"Indian J Hematol Blood Transfus (Apr-June"},{"issue":"12","key":"1984_CR10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jtct.2023.08.032","volume":"29","author":"A Gokarn","year":"2023","unstructured":"Gokarn A, Tembhare PR, Syed H et al (2023) Long-term cryopreservation of Peripheral Blood Stem Cell Harvest using low concentration (4.35%) Dimethyl Sulfoxide with Methyl Cellulose and uncontrolled rate freezing at -80\u00b0C: an effective option in resource-limited settings. Transpl Cell Ther 29(12):777. https:\/\/doi.org\/10.1016\/j.jtct.2023.08.032","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"1984_CR11","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","volume":"7","author":"BK Ragon","year":"2023","unstructured":"Ragon BK, Shah MV, D\u2019Souza A et al (2023) Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv 7(12):2746\u20132757. https:\/\/doi.org\/10.1182\/bloodadvances.2022009138","journal-title":"Blood Adv"},{"issue":"Supplement1","key":"1984_CR12","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1182\/blood-2019-127469","volume":"134","author":"JR Jones","year":"2019","unstructured":"Jones JR, Cairns D, Pawlyn C et al (2019) Myeloma XI trial for newly diagnosed multiple myeloma (NDMM); Long Term Second primary malignancy (SPM) incidence in the context of Lenalidomide Maintenance. Blood 134(Supplement1):3132. https:\/\/ashpublications.org\/blood\/article\/134\/Supplement_1\/3132\/423895\/Title-Myeloma-XI-Trial-forNewly-Diagnosed","journal-title":"Blood"},{"issue":"22","key":"1984_CR13","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T et al (2019) Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma. N Engl J Med 380(22):2104\u20132115. https:\/\/doi.org\/10.1056\/NEJMoa1817249","journal-title":"N Engl J Med"},{"issue":"14","key":"1984_CR14","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood.2022017094","volume":"141","author":"MK Samur","year":"2023","unstructured":"Samur MK, Roncador M, Aktas Samur A et al (2023) High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood 141(14):1724\u20131736. https:\/\/doi.org\/10.1182\/blood.2022017094","journal-title":"Blood"},{"issue":"3","key":"1984_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.4103\/ijc.IJC_272_21","volume":"60","author":"N Yadav","year":"2023","unstructured":"Yadav N, Mirgh SP, Aggarwal M et al (2023) Second stem cell transplantation for treatment of relapsed\/refractory multiple myeloma after first autologous stem cell transplant: a 15-year retrospective institutional analysis. Indian J Cancer 60(3):316\u2013324. https:\/\/doi.org\/10.4103\/ijc.IJC_272_21","journal-title":"Indian J Cancer"},{"issue":"2","key":"1984_CR16","doi-asserted-by":"publisher","first-page":"e13050","DOI":"10.1111\/eci.13050","volume":"49","author":"M Fernandez-Caballero","year":"2019","unstructured":"Fernandez-Caballero M, Salmeron D, Dolores Chirlaque M et al (2019) Increasing therapy\u2010related myeloid neoplasms in multiple myeloma. Eur J Clin Invest 49(2):e13050","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"1984_CR17","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41408-023-00920-9","volume":"13","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Jacob EK, Greiner C et al (2023) The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant. Blood Cancer J 13(1):151. https:\/\/doi.org\/10.1038\/s41408-023-00920-9. Published 2023 Sep 26","journal-title":"Blood Cancer J"},{"issue":"4","key":"1984_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/cncr.31853","volume":"125","author":"P Barth","year":"2019","unstructured":"Barth P, Castillo JJ, Olszewski AJ (2019) Outcomes of secondary solid tumor malignancies among patients with myeloma: a population-based study. Cancer 125(4):550\u2013558. https:\/\/doi.org\/10.1002\/cncr.31853","journal-title":"Cancer"},{"issue":"4","key":"1984_CR19","first-page":"192","volume":"29","author":"L Kumar","year":"2016","unstructured":"Kumar L, Boya RR, Pai R et al (2016) Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J India 29(4):192\u2013199","journal-title":"Natl Med J India"},{"issue":"2","key":"1984_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/10428194.2022.2148214","volume":"64","author":"L Kumar","year":"2023","unstructured":"Kumar L, Sahoo RK, Kumar S et al (2023) Autologous stem cell transplant for multiple myeloma: impact of melphalan dose on the transplant outcome. Leuk Lymphoma 64(2):378\u2013387. https:\/\/doi.org\/10.1080\/10428194.2022.2148214","journal-title":"Leuk Lymphoma"},{"issue":"Supplement1","key":"1984_CR21","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1182\/blood-2023-182563","volume":"142","author":"S Mirgh","year":"2023","unstructured":"Mirgh S, Bagal B, Punatar S et al (2023) Comparison of various stem cell mobilization regimens for multiple myeloma - a 15-Year retrospective institutional analysis from India. Blood 142(Supplement1):2225. https:\/\/doi.org\/10.1182\/blood-2023-182563","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-025-01984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-025-01984-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-025-01984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T21:02:10Z","timestamp":1767992530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-025-01984-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1984"],"URL":"https:\/\/doi.org\/10.1007\/s12288-025-01984-2","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}